Annual report [Section 13 and 15(d), not S-K Item 405]

Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Palobiofarma (Details)

v3.25.1
Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Palobiofarma (Details)
$ in Thousands
12 Months Ended
Sep. 26, 2019
USD ($)
item
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Agreements      
Payments of consideration under RPAs, AAAs and CPPAs   $ 53,000 $ 14,650
Long-term royalty and commercial payment receivables under the cost recovery method   55,936 57,952
Palobiofarma | Royalty Purchase Agreement      
Agreements      
Number of drug candidates | item 6    
Payments of consideration under RPAs, AAAs and CPPAs $ 10,000    
Long-term royalty and commercial payment receivables under the cost recovery method $ 10,000    
Allowance for credit losses   $ 0 $ 0